Video

Dr. Moon on latest progress and unmet needs in prostate cancer care

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Helen Heng-Shan Moon, MD, hematologist/oncologist, Kaiser Permanente Riverside Medical Center, discusses the current state of the prostate cancer paradigm as well as unmet needs in the space.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Advances across urology: Insights from UNC faculty
      Advances across urology: Insights from UNC faculty
      Timothy McClure, MD, on patient selection for focal therapy
      Timothy McClure, MD, on patient selection for focal therapy
      2 experts in this video
      Shared Decision-Making and Treatment Adherence
      Related Content
      FDA grants fast track designation to HLD-0915 in mCRPC
      August 16th 2025

      FDA grants fast track designation to HLD-0915 in mCRPC

      Hannah Clarke
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      August 16th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Study offers insights into optimal patient selection for HIFU in prostate cancer
      August 16th 2025

      Study offers insights into optimal patient selection for HIFU in prostate cancer

      Hannah Clarke
      Dr. Murphy on increasing diversity in cancer clinical trials
      August 16th 2025

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      FDA greenlights phase 1 trial of NSD2 inhibitor in mCRPC
      August 16th 2025

      FDA greenlights phase 1 trial of NSD2 inhibitor in mCRPC

      Hannah Clarke
      Adding metastasis-directed therapy to ADT extends PFS in oligometastatic prostate cancer
      August 16th 2025

      Adding metastasis-directed therapy to ADT extends PFS in oligometastatic prostate cancer

      Hannah Clarke
      © 2025 MJH Life Sciences

      All rights reserved.